| 0.9894 0.029 (3.06%) | 05-22 15:28 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.64 | 1-year : | 1.97 |
| Resists | First : | 1.4 | Second : | 1.69 |
| Pivot price | 1.05  |
|||
| Supports | First : | 0.94 | Second : | 0.78 |
| MAs | MA(5) : | 0.98 |
MA(20) : | 1.09 |
| MA(100) : | 1.55 |
MA(250) : | 2.35 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.9 |
D(3) : | 11.4 |
| RSI | RSI(14): 33.8 |
|||
| 52-week | High : | 4.44 | Low : | 0.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LEXX ] has closed above bottom band by 23.9%. Bollinger Bands are 52.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.02 - 1.03 | 1.03 - 1.03 |
| Low: | 0.93 - 0.94 | 0.94 - 0.95 |
| Close: | 0.95 - 0.97 | 0.97 - 0.98 |
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Mon, 12 May 2025
Lexaria (LEXX) Advances Collaborative Pharmaceutical Research | - GuruFocus
Mon, 12 May 2025
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company - TradingView
Mon, 12 May 2025
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company - Stock Titan
Wed, 30 Apr 2025
Lexaria Bioscience stock hits 52-week low at $1.14 - Investing.com
Mon, 28 Apr 2025
Lexaria Secures $2M Strategic Investment in Clean Direct Offering Amid Market Turbulence - Stock Titan
Fri, 25 Apr 2025
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 1.57e+007 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 522 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.26e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 581 % |
| Return on Equity (ttm) | -77.6 % |
| Qtrly Rev. Growth | 525920 % |
| Gross Profit (p.s.) | 20 |
| Sales Per Share | -145.56 |
| EBITDA (p.s.) | 523200 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 2.41 |
| Dividend | 0 |
| Forward Dividend | 520180 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|